Fig. 2: Within-patient response rates and survival by therapy sequence when switching between VEN + HMA and IDHi-based regimens due to lack/secondary loss of response. | Blood Cancer Journal

Fig. 2: Within-patient response rates and survival by therapy sequence when switching between VEN + HMA and IDHi-based regimens due to lack/secondary loss of response.

From: Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents

Fig. 2

A salvage response was defined as any of CR, CRi, PR, or MLFS. *One patient was included in both groups for separate IDHi-based lines of therapy that immediately preceded and followed, respectively, their VEN + HMA treatment course.

Back to article page